Benefits
Anti-inflammatory commensal Crohn's disease (Sokol 2008 PMID 18936492 PIVOTAL)
Sokol H et al. 2008 (PNAS 105(43):16731-16736, doi:10.1073/pnas.0804812105, PMID 18936492) — FOUNDATIONAL paper identifying F. prausnitzii as ANTI-INFLAMMATORY COMMENSAL via GUT MICROBIOTA ANALYSIS of CROHN DISEASE patients. RESULTS: F. prausnitzii in vitro PBMC stimulation REDUCED IL-12 + IFN-γ production + INCREASED IL-10 secretion. SUPERNATANT BLOCKED NF-κB activation + IL-8 production in Caco-2 cells. Oral administration of LIVE F. prausnitzii or its supernatant MARKEDLY REDUCED severity of TNBS colitis in mice. Foundational pivotal evidence supporting therapeutic potential as next-generation probiotic in CD.
F. prausnitzii depletion in Crohn's disease (cohort association)
F. prausnitzii DEPLETION consistently reported in CROHN'S DISEASE (CD) patients — also reported in ulcerative colitis, IBS, colorectal cancer, type 2 diabetes, obesity, depression. Mechanism: dysbiosis biomarker. Sokol 2008 PIVOTAL identified F. prausnitzii as biomarker of CD prognosis post-resection. Foundational microbiota-based biomarker.
Novel strain functional characterization (Martin 2017 PMC5492426)
Martin R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM, Sokol H, Bermúdez-Humarán LG, Thomas M, Langella P 2017 (Front Microbiol 8:1226, doi:10.3389/fmicb.2017.01226, PMC5492426) — protocol to ISOLATE NOVEL F. PRAUSNITZII STRAINS from feces of healthy volunteers. Deep molecular + metabolic characterization. RESULTS: 2 PHYLOGROUPS + 3 CLUSTERS (16S rRNA). Strains NOT antibacterial producers, NOT hemolytic, weak D-lactate producers. SOME strains adhere to mucin (favors implantation). Foundational strain-specific characterization for next-generation probiotic development.
Next-Generation Probiotic Wiley 2021 review (He 2021)
He 2021 Wiley (Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2021/6666114) — REVIEW positioning F. prausnitzii as 'NEXT-GENERATION PROBIOTIC IN GUT DISEASE IMPROVEMENT'. FMT (fecal microbiota transplantation) influences Bacteroidetes + Firmicutes including F. prausnitzii. Cui et al. step-up FMT for IBD; van Nood demonstrated FMT for recurrent CDI. Foundational positioning paper for F. prausnitzii in next-generation probiotic + FMT context.
FOS prebiotic increases F. prausnitzii in CD (NCT02539849)
NCT02539849 — Hospital Universitari Vall d'Hebron Research Institute trial. PURPOSE: FOS (Fructo-oligosaccharides) prebiotic supplementation in CROHN'S DISEASE patients to INCREASE F. prausnitzii counts in fecal samples. STATUS: COMPLETED. Mechanism: indirect approach via PREBIOTIC stimulation of native F. prausnitzii (vs direct probiotic supplementation). Foundational prebiotic-based approach to F. prausnitzii enhancement.
Butyrate production (major SCFA producer)
F. prausnitzii is a MAJOR PRODUCER of BUTYRATE — short-chain fatty acid critical for COLONOCYTE energy + barrier function + anti-inflammatory effects. Mechanism: butyrate as primary energy source for colonocytes (60-70%) + HDAC inhibition + tight junction support. Distinguishing among gut commensals.
NF-κB blockade + IL-8 reduction (mechanism)
Sokol 2008: F. PRAUSNITZII SUPERNATANT exerts antiinflammatory effects on Caco-2 cells via BLOCKING NF-κB ACTIVATION + IL-8 PRODUCTION. Mechanism: secreted metabolites with anti-inflammatory bioactivity beyond live bacterial activity. Foundational secreted-metabolite mechanism.
Mechanism of action
Butyrate production (major SCFA)
F. prausnitzii is MAJOR butyrate producer — distinguishing among gut commensals. Mechanism: butyrate as colonocyte primary energy source (60-70%) + HDAC inhibition + tight junction integrity + anti-inflammatory effects. Foundational metabolite mechanism.
Secreted metabolite anti-inflammatory bioactivity
F. prausnitzii SUPERNATANT exerts anti-inflammatory effects independent of live cells — blocks NF-κB activation + IL-8 production. Mechanism: secreted metabolite bioactivity allowing potential POSTBIOTIC applications. Distinguishing for non-viable formulation potential.
IL-12/IFN-γ reduction + IL-10 induction
F. prausnitzii in PBMC stimulation REDUCES IL-12 + IFN-γ + INCREASES IL-10. Mechanism: anti-inflammatory cytokine profile shift. Foundation immunomodulation.
Treg cell induction
F. prausnitzii promotes regulatory T cell (Treg) induction — supports immune homeostasis + tolerance. Mechanism: anti-inflammatory immune cell expansion.
Gut barrier integrity + tight junction support
Butyrate + secreted metabolites support tight junction proteins (claudins, occludin, ZO-1). Mechanism: barrier function enhancement particularly important in IBD context.
Mucin adherence (some strains)
Martin 2017: SOME F. prausnitzii strains adhere to MUCIN — favors durable implantation + effective probiotic activity. Mechanism: strain-specific mucin-binding. Important for strain selection in next-generation probiotic development.
Strict anaerobe (formulation challenge)
F. prausnitzii is STRICT ANAEROBE — DIFFICULT TO FORMULATE as commercial live probiotic supplement. Mechanism limitation: oxygen sensitivity requires specialized delivery systems. Practical pharmaceutical challenge for next-generation probiotic translation.
Clinical trials
Foundational paper (Sokol H et al. 2008, PNAS 105(43):16731-16736, doi:10.1073/pnas.0804812105, PMID 18936492).
Crohn disease patients gut microbiota analysis + in vitro PBMC stimulation + Caco-2 cell experiments + TNBS colitis mouse model.
F. PRAUSNITZII REDUCED IL-12 + IFN-γ + INCREASED IL-10 in PBMC stimulation. SUPERNATANT BLOCKED NF-κB activation + IL-8 production in Caco-2. ORAL ADMINISTRATION of LIVE F. prausnitzii or SUPERNATANT MARKEDLY REDUCED severity of TNBS colitis in mice. Foundational pivotal evidence for next-generation probiotic potential. PRECLINICAL evidence supporting therapeutic translation.
Single-group interventional trial (NCT02539849, Hospital Universitari Vall d'Hebron Research Institute). Status: COMPLETED.
Crohn's disease patients aged 18-65. Intervention: FOS (fructo-oligosaccharides) prebiotic supplementation. Concurrent adalimumab in some patients.
Demonstrated FOS supplementation INCREASES F. PRAUSNITZII COUNTS in fecal samples from Crohn's disease patients. Foundational prebiotic-based approach to F. prausnitzii enhancement — indirect mechanism distinct from direct probiotic supplementation. Important translational approach given strict anaerobe formulation challenge.
Microbiology characterization (Martin R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM, Sokol H, Bermúdez-Humarán LG, Thomas M, Langella P 2017, Front Microbiol 8:1226, doi:10.3389/fmicb.2017.01226, PMC5492426).
Novel F. prausnitzii strains isolated from feces of HEALTHY VOLUNTEERS. 16S rRNA + molecular + metabolic characterization.
STRAINS classified into 2 PHYLOGROUPS + 3 CLUSTERS (16S rRNA). NOT antibacterial producers, NOT hemolytic, weak D-lactate producers. SOME adhere to MUCIN (favors implantation). 2 GENOMOSPECIES/GENOMOVARS proposed. Foundational strain-specific characterization enabling next-generation probiotic development. Multi-investigator collaboration.
About this ingredient
FAECALIBACTERIUM PRAUSNITZII is a MAJOR member of FIRMICUTES PHYLUM + ONE OF MOST ABUNDANT bacteria in HEALTHY HUMAN MICROBIOTA (~5% of total fecal microbiota in healthy adults). NEXT-GENERATION PROBIOTIC candidate — depletion CONSISTENTLY REPORTED in CROHN'S DISEASE patients + also in UC, IBS, colorectal cancer, type 2 diabetes, obesity, depression. NOT YET COMMERCIALLY AVAILABLE as live probiotic supplement — STRICT ANAEROBE difficult to formulate (oxygen sensitivity requires specialized delivery systems). PIVOTAL CLINICAL EVIDENCE: SOKOL H ET AL. 2008 PMID 18936492 PMC2575488 (PNAS 105(43):16731-16736, doi:10.1073/pnas.0804812105) FOUNDATIONAL paper identifying F. prausnitzii as ANTI-INFLAMMATORY COMMENSAL via gut microbiota analysis of Crohn disease patients. RESULTS: in vitro PBMC stimulation REDUCED IL-12 + IFN-γ + INCREASED IL-10; SUPERNATANT BLOCKED NF-κB + IL-8 in Caco-2; oral administration of LIVE F. prausnitzii or SUPERNATANT MARKEDLY REDUCED TNBS colitis severity in mice. MARTIN 2017 PMC5492426 (Front Microbiol 8:1226, doi:10.3389/fmicb.2017.01226) — multi-investigator (Sokol + Langella) novel strain isolation + characterization from healthy volunteers; 2 phylogroups + 3 clusters; 2 genomospecies/genomovars; NOT antibacterial producers + NOT hemolytic + weak D-lactate; SOME mucin-adherent. NCT02539849 FOS prebiotic in Crohn's disease (Hospital Universitari Vall d'Hebron, COMPLETED) — INDIRECT enhancement via FOS supplementation INCREASES F. prausnitzii fecal counts. HE 2021 Wiley (Canadian J Infect Dis Med Microbiol, doi:10.1155/2021/6666114) — review positioning F. prausnitzii as NEXT-GENERATION PROBIOTIC. FMT (van Nood + Cui IBD step-up FMT) influences Bacteroidetes + Firmicutes including F. prausnitzii.
MECHANISMS: BUTYRATE PRODUCTION (major SCFA producer — colonocyte primary energy source 60-70%, HDAC inhibition, tight junction integrity); SECRETED METABOLITE anti-inflammatory bioactivity (NF-κB blockade + IL-8 reduction independent of live cells — POSTBIOTIC potential); IL-12/IFN-γ reduction + IL-10 induction; Treg cell induction; gut barrier integrity + tight junction support; MUCIN ADHERENCE (some strains — favors implantation); STRICT ANAEROBE formulation challenge (oxygen sensitivity). EVIDENCE: 2/5 reflects: (1) SOKOL 2008 PIVOTAL PNAS preclinical foundational evidence — anti-inflammatory commensal identification + TNBS colitis preclinical efficacy, (2) MARTIN 2017 multi-investigator strain characterization for next-generation development, (3) NCT02539849 FOS PREBIOTIC INDIRECT clinical trial (COMPLETED) — IBD population, (4) HE 2021 Wiley NEXT-GENERATION PROBIOTIC review positioning, (5) WELL-CHARACTERIZED butyrate production + secreted metabolite + immunomodulation mechanisms, (6) ABUNDANT cohort/association evidence linking F. prausnitzii depletion to multiple diseases (CD, UC, IBS, CRC, T2D, obesity, depression), (7) HONEST LIMITATIONS — NOT YET COMMERCIALLY AVAILABLE as live probiotic; mostly preclinical + cohort evidence; strict anaerobe formulation challenge; FMT-based + prebiotic-based indirect approaches dominate human evidence, (8) NO direct human probiotic RCTs (in contrast to L. reuteri DSM 17938, L. crispatus CTV-05, etc.), (9) industry-academic translational research emerging, (10) higher-evidence than typical 'gut commensal' but lower-evidence than commercial probiotics due to formulation barriers. SAFETY: Extensive natural commensal status supports safety; specific probiotic supplementation safety still emerging. Best positioned as: (a) UNDERSTANDING F. PRAUSNITZII as biomarker of CD prognosis + IBD dysbiosis severity, (b) PREBIOTIC FOS approach to enhance native F. prausnitzii (NCT02539849 evidence), (c) FMT-based approaches in clinical IBD context (consult specialist), (d) MICROBIOME DIVERSITY understanding (~5% of healthy fecal microbiota target), (e) BUTYRATE-PRODUCING COMMENSAL category (relevant to butyrate prodrug like tributyrin), (f) NEXT-GENERATION PROBIOTIC DEVELOPMENT awareness (commercial products emerging), (g) NOT currently available as standalone supplement — INDIRECT enhancement via prebiotics + diet + FMT current pathway, (h) DIETARY SUPPORT: high-fiber + plant-diverse diet supports native F. prausnitzii populations, (i) IMMUNOCOMPROMISED: relevant if/when commercial probiotic available, (j) lower-evidence for direct probiotic supplementation due to formulation barriers; HIGH-evidence for biomarker/dysbiosis biology. Honest framing: Faecalibacterium prausnitzii is one of the MOST IMPORTANT gut commensals from research perspective — Sokol 2008 PNAS foundational paper established anti-inflammatory commensal role + TNBS colitis preclinical efficacy.
CRITICAL HONEST LIMITATION: NOT YET COMMERCIALLY AVAILABLE as live probiotic supplement due to strict anaerobe formulation challenge. F. prausnitzii depletion biomarker evidence in Crohn's disease + multiple other diseases is genuinely robust + clinically relevant — supports gut microbiota dysbiosis understanding. Indirect enhancement strategies (FOS prebiotics per NCT02539849, FMT in clinical context, dietary support) are CURRENT translational pathway. Martin 2017 strain characterization + multi-investigator next-generation probiotic development positions for future commercial translation. Wiley 2021 review positioning supports research category. Reasonable to UNDERSTAND F. prausnitzii role + indirect enhancement strategies — but DIRECT live probiotic supplementation NOT CURRENTLY AVAILABLE. Position: research/biomarker awareness + dietary/prebiotic indirect support strategy + emerging clinical translation.